Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity-Reference-Cited by-同舟云学术

Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity

Published:2020-01-31 Issue:5 Volume:6 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Ma Xiao¹²³⁴^ORCID,Zhu Ping¹²,Ding Yonghe¹²,Zhang Hong¹²⁵^ORCID,Qiu Qi¹²⁶^ORCID,Dvornikov Alexey V.¹²^ORCID,Wang Zheng⁷^ORCID,Kim Maengjo¹²,Wang Yong¹²⁸,Lowerison Matthew⁹^ORCID,Yu Yue¹⁰,Norton Nadine¹¹,Herrmann Joerg²,Ekker Stephen C.¹³⁴^ORCID,Hsiai Tzung K.¹²,Lin Xueying¹²,Xu Xiaolei¹²³⁴^ORCID

Affiliation:

1. Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.

2. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

3. Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN, USA.

4. Mayo Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.

5. Clinical Center for Gene Diagnosis and Therapy, The Second Xiangya Hospital of Central South University, Changsha, China.

6. Institute of Clinical Pharmacology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

7. Department of Medicine, Mayo Clinic, Rochester, MN, USA.

8. Institute of Life Science, Beijing University of Chinese Medicine, Beijing, China.

9. Department of Urology, Mayo Clinic, Rochester, MN, USA.

10. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

11. Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.

12. School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

Abstract

RXRA is an endothelial- and early stage–predominant therapeutic target for treating anthracycline-induced cardiotoxicity.

Funder

NIH Office of the Director

American Heart Association

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference45 articles.

1. Anthracycline Chemotherapy and Cardiotoxicity

2. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

3. Identification of the molecular basis of doxorubicin-induced cardiotoxicity

4. Doxorubicin Cardiomyopathy

5. Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kidney transcriptome and cystic kidney disease genes in zebrafish;Frontiers in Physiology;2023-05-04

2. Assessment of palmitic acid toxicity to animal hearts and other major organs based on acute toxicity, network pharmacology, and molecular docking;Computers in Biology and Medicine;2023-05

3. Molecular mechanisms of anthracycline induced cardiotoxicity: Zebrafish come into play;Frontiers in Cardiovascular Medicine;2023-03-10

4. m6A demethylase ALKBH5 attenuates doxorubicin-induced cardiotoxicity via posttranscriptional stabilization of Rasal3;iScience;2023-03

5. Synergistic Effects of Ginsenoside Rb3 and Ferruginol in Ischemia-Induced Myocardial Infarction;International Journal of Molecular Sciences;2022-12-14